Streetbeat News

Revenues

AMLX

Four analysts have recently shared their views on Amylyx Pharma (NASDAQ:AMLX), with ratings ranging from bullish to somewhat bullish. The average 12-month price target is now $33.00, down from $36.50, indicating a 9.59% decrease. Amylyx Pharma has shown significant revenue growth of 395.54% as of December 31, 2023, and outperforms in net margin, ROE, and ROA, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 1:00 pm

ASB

Analyst ratings for Associated Banc (NYSE:ASB) have shown a mix of opinions, with recent updates indicating a positive shift in sentiment. The average 12-month price target has been raised to $23.25, reflecting an 8.14% increase from the previous target. Analysts from Barclays, Raymond James, Piper Sandler, and RBC Capital have adjusted their ratings and price targets, suggesting a cautiously optimistic outlook. Despite this, Associated Banc faces financial challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 1:00 pm

TSM

Taiwan Semiconductor (TSM) reported an 11.3% year-over-year increase in revenue for February 2024, reaching NT$181.65 billion. For the January-February 2024 period, revenue totaled NT$397.43 billion, marking a 9.4% increase from the same period in 2023.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:50 pm

VSCO

Victoria's Secret & Co. (NYSE:VSCO) stock fell in premarket trading after a 30% loss the previous day. Over the last year, VSCO shares dropped 46% against the S&P 500's 30% gain. The company missed Q4 revenue estimates and forecasted a mid-single digit sales decrease for Q1 2024, with adjusted operating income between $10 million to $35 million. Analysts highlight challenges in the intimates market and a tough operating environment, expecting pressure through at least the first half of 2024.

Portfolio Pulse from Nabaparna Bhattacharya

March 08, 2024 | 12:07 pm

COOK

Traeger's shares dropped following the announcement of disappointing Q4 EPS results and lower than expected revenue guidance for Q1 and FY24.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:06 pm

ARHS

Recent analysis of Arhaus (NASDAQ:ARHS) by 5 analysts shows a generally positive outlook, with an average 12-month price target of $15.7, reflecting a 13.11% increase from the previous target. Analysts from Barclays, Telsey Advisory Group, and B of A Securities have raised their price targets, indicating optimism about the company's performance. Arhaus's financials reveal a positive revenue trend, superior net margin, and ROE compared to industry averages, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 12:01 pm

BKU

BankUnited (NYSE:BKU) has been evaluated by 7 analysts over the last three months, showing a mix of indifferent and bearish sentiments. The average 12-month price target is $30.29, slightly up from the previous $30.00. Analyst actions include adjustments to ratings and price targets, reflecting their response to BankUnited's performance and market conditions. The company's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are also discussed, providing a comprehensive view of its market standing.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 12:01 pm

CHWY

Recent analyst ratings for Chewy (NYSE:CHWY) show a predominantly bullish outlook, with 4 bullish and 1 somewhat bullish ratings in the last three months. The average 12-month price target for CHWY has been raised to $28.6, indicating an 8.62% increase from the previous target of $26.33. Analysts from firms like Needham, Goldman Sachs, Barclays, and Jefferies have adjusted their price targets and ratings, reflecting their views on Chewy's market position and financial health. Chewy, a leading e-commerce pet care retailer, reported a revenue growth rate of 8.15% as of October 31, 2023, and has shown strong financial health despite a net margin of -1.31% and below-industry benchmarks for ROE and ROA.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 12:00 pm

COLB

Analyst ratings for Columbia Banking System (NASDAQ:COLB) show a shift towards a more cautious stance, with a significant decrease in the average price target over the last quarter. Recent evaluations by analysts from firms like Barclays, UBS, and JP Morgan reflect adjustments to their ratings and price targets, indicating a bearish sentiment. Despite this, Columbia Banking System has shown solid revenue growth and operates a substantial banking network across several states, but faces challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 12:00 pm

GCO

Genesco projects a significant decrease in its adjusted EPS for FY25, forecasting a range of $0.60 to $1.00, compared to the estimated $2.53. The company also anticipates a 2% to 3% decline in sales for the same fiscal year.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 11:54 am